Your browser doesn't support javascript.
loading
Prevalence of RPGR-Mediated Retinal Dystrophy in an Unselected Cohort of Over 5000 Patients.
Tuupanen, Sari; Gall, Kimberly; Sistonen, Johanna; Saarinen, Inka; Kämpjärvi, Kati; Wells, Kirsty; Merkkiniemi, Katja; von Nandelstadh, Pernilla; Sarantaus, Laura; Känsäkoski, Johanna; Mårtenson, Emma; Västinsalo, Hanna; Schleit, Jennifer; Sankila, Eeva-Marja; Kere, Annakarin; Junnila, Heidi; Siivonen, Pauli; Andreevskaya, Margarita; Kytölä, Ville; Muona, Mikko; Salmenperä, Pertteli; Myllykangas, Samuel; Koskenvuo, Juha; Alastalo, Tero-Pekka.
  • Tuupanen S; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Gall K; Blueprint Genetics Inc, Seattle, WA, USA.
  • Sistonen J; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Saarinen I; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Kämpjärvi K; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Wells K; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Merkkiniemi K; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • von Nandelstadh P; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Sarantaus L; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Känsäkoski J; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Mårtenson E; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Västinsalo H; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Schleit J; Blueprint Genetics Inc, Seattle, WA, USA.
  • Sankila EM; Helsinki University Eye Hospital, Outpatient Clinic for Hereditary Eye Diseases, Helsinki, Finland.
  • Kere A; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Junnila H; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Siivonen P; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Andreevskaya M; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Kytölä V; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Muona M; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Salmenperä P; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Myllykangas S; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Koskenvuo J; Blueprint Genetics OY, Keilaranta, Espoo, Finland.
  • Alastalo TP; Blueprint Genetics Inc, Seattle, WA, USA.
Transl Vis Sci Technol ; 11(1): 6, 2022 01 03.
Article en En | MEDLINE | ID: mdl-34985506
Purpose: Comprehensive genetic testing for inherited retinal dystrophy (IRD) is challenged by difficult-to-sequence genomic regions, which are often mutational hotspots, such as RPGR ORF15. The purpose of this study was to evaluate the diagnostic contribution of RPGR variants in an unselected IRD patient cohort referred for testing in a clinical diagnostic laboratory. Methods: A total of 5201 consecutive patients were analyzed with a clinically validated next-generation sequencing (NGS)-based assay, including the difficult-to-sequence RPGR ORF15 region. Copy number variant (CNV) detection from NGS data was included. Variant interpretation was performed per the American College of Medical Genetics and Genomics guidelines. Results: A confirmed molecular diagnosis in RPGR was found in 4.5% of patients, 24.0% of whom were females. Variants in ORF15 accounted for 74% of the diagnoses; 29% of the diagnostic variants were in the most difficult-to-sequence central region of ORF15 (c.2470-3230). Truncating variants made up the majority (91%) of the diagnostic variants. CNVs explained 2% of the diagnostic cases, of which 80% were one- or two-exon deletions outside of ORF15. Conclusions: Our findings indicate that high-throughput, clinically validated NGS-based testing covering the difficult-to-sequence region of ORF15, in combination with high-resolution CNV detection, can help to maximize the diagnostic yield for patients with IRD. Translational Relevance: These results demonstrate an accurate and scalable method for the detection of RPGR-related variants, including the difficult-to-sequence ORF15 hotspot, which is relevant given current and emerging therapeutic opportunities.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas del Ojo / Distrofias Retinianas Tipo de estudio: Diagnostic_studies / Guideline / Prevalence_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteínas del Ojo / Distrofias Retinianas Tipo de estudio: Diagnostic_studies / Guideline / Prevalence_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2022 Tipo del documento: Article